{"product_id":"management-of-acute-coronary-syndromes-hardback-9780470725573","title":"Management of Acute Coronary Syndromes (Hardback) 9780470725573","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eManagement of Acute Coronary Syndromes\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eEli Gelfand (Author), Christopher Cannon (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470725573, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 17 April 2009\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e238 pages\u003cbr\u003e21.8 x 13.7 x 1.8 cm, 0.408 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eAcute Coronary Syndrome covers the spectrum of clinical conditions ranging from unstable angina to non-ST elevation myocardial infarction and ST elevation myocardial infarction. These life-threatening disorders are a major cause of emergency medical care, hospitalization and mortality. \u003ci\u003eManagement of Acute Coronary Syndromes\u003c\/i\u003e is designed to provide busy clinicians with a comprehensive guide to the investigation, diagnosis and treatment of these syndromes. It encompasses the latest technologies, including the use of biomarkers and non-invasive imaging procedures.  \u003cp\u003eFor each condition, the reader is taken through all of the therapeutic options available; in each case the indications and contraindications are evaluated in the light of the latest clinical trials. Potential complications are dealt with in a similar fashion, permitting the reader to anticipate and manage problems as they arise. The authors also present evidence-based recommendations for long-term care of at-risk patients, encompassing pharmacologic therapies and lifestyle management.\u003c\/p\u003e \u003cp\u003eThe book concludes with a comprehensive collection of appendices that include treatment algorithms, risk scores and a summary of the latest management guidelines.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eManagement of Acute Coronary Syndromes\u003c\/i\u003e is the most up to date and comprehensive evidence-based guide to managing acute coronary syndromes, in a compact and usable format.  It will be of interest to busy specialist physicians in cardiovascular medicine, cardiac and vascular surgery, and critical care, as well as primary care physicians and hospitalists who care for patients with these syndromes.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eList of contributors xiii\u003c\/p\u003e \u003cp\u003eForeword xv\u003cbr\u003e \u003ci\u003eEugene Braunwald\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Pathophysiology of acute coronary syndromes 1\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlisa B. Rosen and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003eFormation of atherosclerotic plaque 2\u003c\/p\u003e \u003cp\u003ePlaque instability and the development of ACS 5\u003c\/p\u003e \u003cp\u003eMyocardial ischemia 7\u003c\/p\u003e \u003cp\u003eThrombus formation 7\u003c\/p\u003e \u003cp\u003ePlatelets 7\u003c\/p\u003e \u003cp\u003eSecondary hemostasis 9\u003c\/p\u003e \u003cp\u003eDynamic obstruction 10\u003c\/p\u003e \u003cp\u003eProgressive mechanical obstruction 10\u003c\/p\u003e \u003cp\u003eInflammation 11\u003c\/p\u003e \u003cp\u003eSecondary unstable angina 11\u003c\/p\u003e \u003cp\u003eReferences 11\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Diagnosis of acute coronary syndrome 13\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Alisa B. Rosen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 13\u003c\/p\u003e \u003cp\u003eDefinition of myocardial infarction 13\u003c\/p\u003e \u003cp\u003eHistory 14\u003c\/p\u003e \u003cp\u003eRisk factors 17\u003c\/p\u003e \u003cp\u003ePhysical examination 17\u003c\/p\u003e \u003cp\u003eElectrocardiography 19\u003c\/p\u003e \u003cp\u003eThe pathophysiologic basis of ST segment\u003c\/p\u003e \u003cp\u003echanges during ischemia 19\u003c\/p\u003e \u003cp\u003eElectrocardiography in ST-elevation MI and identification of the infarct-related artery 20\u003c\/p\u003e \u003cp\u003eElectrocardiography in unstable angina and NSTEMI 26\u003c\/p\u003e \u003cp\u003eCardiac biomarkers 26\u003c\/p\u003e \u003cp\u003eNoninvasive imaging 29\u003c\/p\u003e \u003cp\u003eEchocardiography 29\u003c\/p\u003e \u003cp\u003eMyocardial perfusion imaging 30\u003c\/p\u003e \u003cp\u003eCoronary computed tomography 30\u003c\/p\u003e \u003cp\u003eCardiovascular magnetic resonance imaging 31\u003c\/p\u003e \u003cp\u003eStress testing for diagnosis of ACS 32\u003c\/p\u003e \u003cp\u003eOverall diagnostic pathway for ACS 32\u003c\/p\u003e \u003cp\u003eReferences 34\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Unstable angina and non-ST-elevation myocardial infarction 37\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Christopher P. Cannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 37\u003c\/p\u003e \u003cp\u003eCauses of UA\/NSTEMI 37\u003c\/p\u003e \u003cp\u003ePresentation of UA\/NSTEMI 38\u003c\/p\u003e \u003cp\u003eGeneral strategies in management of UA\/NSTEMI 39\u003c\/p\u003e \u003cp\u003eRisk stratification of patients with UA\/NSTEMI 40\u003c\/p\u003e \u003cp\u003eInitial management of UA\/NSTEMI in the emergency department 42\u003c\/p\u003e \u003cp\u003ePharmacologic treatment of ischemia in UA\/NSTEMI 43\u003c\/p\u003e \u003cp\u003eBeta-blockers 44\u003c\/p\u003e \u003cp\u003eNitrates 44\u003c\/p\u003e \u003cp\u003eCalcium channel blockers 45\u003c\/p\u003e \u003cp\u003eAngiotensin-converting enzyme inhibitors 45\u003c\/p\u003e \u003cp\u003eMorphine 46\u003c\/p\u003e \u003cp\u003eOxygen 46\u003c\/p\u003e \u003cp\u003eInvasive versus conservative strategy 46\u003c\/p\u003e \u003cp\u003eAntiplatelet therapy in UA\/NSTEMI 49\u003c\/p\u003e \u003cp\u003eAspirin 54\u003c\/p\u003e \u003cp\u003eClopidogrel 55\u003c\/p\u003e \u003cp\u003ePrasugrel 57\u003c\/p\u003e \u003cp\u003eGlycoprotein IIb\/IIIa inhibitors 58\u003c\/p\u003e \u003cp\u003eAnticoagulant therapy in UA\/NSTEMI 61\u003c\/p\u003e \u003cp\u003eUnfractionated heparin 61\u003c\/p\u003e \u003cp\u003eEnoxaparin 62\u003c\/p\u003e \u003cp\u003eDirect thrombin inhibitors 65\u003c\/p\u003e \u003cp\u003eFondaparinux 66\u003c\/p\u003e \u003cp\u003eOral anticoagulation in UA\/NSTEMI 67\u003c\/p\u003e \u003cp\u003eFibrinolysis in UA\/NSTEMI 68\u003c\/p\u003e \u003cp\u003eEarly lipid-lowering therapy in patients with UA\/NSTEMI 68\u003c\/p\u003e \u003cp\u003ePredischarge noninvasive risk stratification after UA\/NSTEMI 69\u003c\/p\u003e \u003cp\u003eOverall management of UA\/NSTEMI 71\u003c\/p\u003e \u003cp\u003eReferences 71\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 ST-segment-elevation myocardial infarction 79\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Christopher P. Cannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 79\u003c\/p\u003e \u003cp\u003eGlobal treatment goals in STEMI 79\u003c\/p\u003e \u003cp\u003ePrehospital management and triage 80\u003c\/p\u003e \u003cp\u003eTransport decisions 82\u003c\/p\u003e \u003cp\u003eManagement prior to reperfusion 82\u003c\/p\u003e \u003cp\u003ePrimary reperfusion therapy for STEMI 83\u003c\/p\u003e \u003cp\u003eFibrinolysis 83\u003c\/p\u003e \u003cp\u003eCombination fibrinolysis 86\u003c\/p\u003e \u003cp\u003eMarkers of fibrinolysis effectiveness 86\u003c\/p\u003e \u003cp\u003eComplications of fibrinolysis 88\u003c\/p\u003e \u003cp\u003ePrimary percutaneous coronary intervention 88\u003c\/p\u003e \u003cp\u003eComparison of PCI with fibrinolysis 90\u003c\/p\u003e \u003cp\u003eTiming of primary PCI 91\u003c\/p\u003e \u003cp\u003ePCI following fibrinolytic therapy 94\u003c\/p\u003e \u003cp\u003eRescue PCI 94\u003c\/p\u003e \u003cp\u003eFacilitated PCI 94\u003c\/p\u003e \u003cp\u003eRoutine PCI after successful fibrinolysis 96\u003c\/p\u003e \u003cp\u003eOverall reperfusion strategy 97\u003c\/p\u003e \u003cp\u003eCoronary artery bypass grafting for treatment of STEMI 98\u003c\/p\u003e \u003cp\u003eAdjunctive pharmacologic treatment of STEMI 98\u003c\/p\u003e \u003cp\u003eAntiplatelet agents 98\u003c\/p\u003e \u003cp\u003eAnticoagulation therapy 101\u003c\/p\u003e \u003cp\u003eOther adjunctive therapy 105\u003c\/p\u003e \u003cp\u003eHospital care following successful reperfusion 110\u003c\/p\u003e \u003cp\u003eReferences 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Special considerations in acute coronary syndromes 123\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJason Ryan and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSecondary unstable angina 123\u003c\/p\u003e \u003cp\u003eAcute coronary syndrome in patients with diabetes mellitus 123\u003c\/p\u003e \u003cp\u003eGeneral considerations 123\u003c\/p\u003e \u003cp\u003ePrimary ACS therapy in diabetics 124\u003c\/p\u003e \u003cp\u003eGlycemic control in diabetics with ACS 125\u003c\/p\u003e \u003cp\u003eCoronary revascularization in diabetics 126\u003c\/p\u003e \u003cp\u003eMetabolic syndrome and ACS 127\u003c\/p\u003e \u003cp\u003eChronic kidney disease in ACS 127\u003c\/p\u003e \u003cp\u003eYoung patients with ACS 130\u003c\/p\u003e \u003cp\u003eACS in the setting of cocaine use 130\u003c\/p\u003e \u003cp\u003eACS in patients with normal coronary arteries or mild CAD 132\u003c\/p\u003e \u003cp\u003eMyocarditis 132\u003c\/p\u003e \u003cp\u003eAcute transient apical ballooning syndrome 133\u003c\/p\u003e \u003cp\u003ePostoperative ACS 134\u003c\/p\u003e \u003cp\u003eACS in a pregnant woman 135\u003c\/p\u003e \u003cp\u003eHyperthyroidism and ACS 136\u003c\/p\u003e \u003cp\u003eACS in patients exposed to radiation 137\u003c\/p\u003e \u003cp\u003eTrauma and ACS 137\u003c\/p\u003e \u003cp\u003eReferences 137\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Complications of acute coronary syndrome 141\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJan M. Pattanayak and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 141\u003c\/p\u003e \u003cp\u003ePump failure 141\u003c\/p\u003e \u003cp\u003eGeneral principle 141\u003c\/p\u003e \u003cp\u003eClinical presentation 142\u003c\/p\u003e \u003cp\u003ePrognosis 144\u003c\/p\u003e \u003cp\u003eTreatment 144\u003c\/p\u003e \u003cp\u003eRight ventricular infarction 148\u003c\/p\u003e \u003cp\u003eIntroduction 148\u003c\/p\u003e \u003cp\u003eClinical presentation 148\u003c\/p\u003e \u003cp\u003eDiagnosis 149\u003c\/p\u003e \u003cp\u003eManagement 150\u003c\/p\u003e \u003cp\u003ePrognosis 152\u003c\/p\u003e \u003cp\u003eMechanical complications of ACS 152\u003c\/p\u003e \u003cp\u003eIntroduction 152\u003c\/p\u003e \u003cp\u003eLeft ventricular free wall rupture 152\u003c\/p\u003e \u003cp\u003eVentricular septal rupture 153\u003c\/p\u003e \u003cp\u003eAcute mitral regurgitation 154\u003c\/p\u003e \u003cp\u003eLeft ventricular aneurysm 155\u003c\/p\u003e \u003cp\u003eLeft ventricular pseudoaneurysm 157\u003c\/p\u003e \u003cp\u003ePericardial complications 157\u003c\/p\u003e \u003cp\u003eArrhythmic complications of ACS 159\u003c\/p\u003e \u003cp\u003eBradyarrhythmias 159\u003c\/p\u003e \u003cp\u003eAtrial fibrillation 163\u003c\/p\u003e \u003cp\u003eVentricular tachycardia and fibrillation 163\u003c\/p\u003e \u003cp\u003eComplications involving bleeding 164\u003c\/p\u003e \u003cp\u003eComplications of percutaneous coronary intervention 165\u003c\/p\u003e \u003cp\u003eReferences 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Post-hospitalization care of patients with acute coronary syndrome 173\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJersey Chen and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 173\u003c\/p\u003e \u003cp\u003ePharmacologic measures 173\u003c\/p\u003e \u003cp\u003eAspirin 173\u003c\/p\u003e \u003cp\u003eClopidogrel 174\u003c\/p\u003e \u003cp\u003eBeta adrenergic blockade 177\u003c\/p\u003e \u003cp\u003eRenin–angiotensin–aldosterone inhibitors 179\u003c\/p\u003e \u003cp\u003eLipid-lowering therapy 185\u003c\/p\u003e \u003cp\u003eWarfarin 189\u003c\/p\u003e \u003cp\u003eInfluenza vaccination 192\u003c\/p\u003e \u003cp\u003eMedications of limited benefit to patients following ACS 192\u003c\/p\u003e \u003cp\u003eVitamins\/antioxidants 192\u003c\/p\u003e \u003cp\u003eEstrogen replacement therapy 192\u003c\/p\u003e \u003cp\u003eNonsteroidal anti-inflammatory agents and related compounds 194\u003c\/p\u003e \u003cp\u003eNonpharmacologic measures 195\u003c\/p\u003e \u003cp\u003eAntiarrhythmic devices 195\u003c\/p\u003e \u003cp\u003eTherapy of comorbidities following ACS 198\u003c\/p\u003e \u003cp\u003eDiabetes mellitus 198\u003c\/p\u003e \u003cp\u003eHypertension 199\u003c\/p\u003e \u003cp\u003eDepression 199\u003c\/p\u003e \u003cp\u003eLifestyle recommendations following ACS 200\u003c\/p\u003e \u003cp\u003eGeneral physical activity and structured cardiac rehabilitation 200\u003c\/p\u003e \u003cp\u003eSexual activity after ACS 201\u003c\/p\u003e \u003cp\u003eSmoking cessation 201\u003c\/p\u003e \u003cp\u003eDiet\/nutrition and weight loss 202\u003c\/p\u003e \u003cp\u003eReferences 204\u003c\/p\u003e \u003cp\u003eAppendix 209\u003c\/p\u003e \u003cp\u003eIndex 217\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Medicine: general issues [\u003ca title=\"See our other books on Medicine: general issues\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Medicine:%20general%20issues%20%5BMB%5D%22\"\u003eMB\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278024700184,"sku":"9780470725573","price":78.59,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470725573.jpg?v=1781456119","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/management-of-acute-coronary-syndromes-hardback-9780470725573","provider":"Freshly Printed Books","version":"1.0","type":"link"}